FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES

FIRST LINE 5-FU-BASED CHEMOTHERAPY WITH/WITHOUT BEVACIZUMAB FOR METASTATIC COLORECTAL CANCER: TISSUE BIOMARKER CANDIDATES

Purpose: Colorectal cancer is the second leading cause of cancer mortality in the USA. According to Bulgarian National Statistics Institute, 2370 colon and 1664 rectal cancer cases were diagnosed in 2012 with total number of patients 29995. Adding bevacizumab to chemotherapy in patients with metasta...

Full description

Bibliographic Details
Main Authors: Assia Konsoulova, Ivan Donev, Nikolay Conev, Sonya Draganova, Nadezhda Petrova, Eleonora Dimitrova, Hristo Popov, Kameliya Bratoeva, Petar Ghenev
Format: Article
Language:English
Published: Peytchinski Publishing 2016-03-01
Series:Journal of IMAB
Subjects:
colorectal
bevacizumab
VEGFR-2
biomarkers
neuropillin-1
Online Access:http://www.journal-imab-bg.org/issues-2016/issue1/JofIMAB_2016-22-1p1039-1044.pdf

Internet

http://www.journal-imab-bg.org/issues-2016/issue1/JofIMAB_2016-22-1p1039-1044.pdf

Similar Items